NanoViricides (NYSE: NNVC) enters at-the-market sales deal for stock
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
NanoViricides, Inc. entered into an At Market Issuance Sales Agreement with D. Boral Capital LLC, permitting the company to issue and sell shares of its common stock from time to time in an “at the market” offering under its existing Form S-3 shelf registration statement. Sales, if any, may occur on the NYSE American or other trading markets, or in privately negotiated transactions with the company’s prior written consent, based on parameters set in placement notices.
The company will pay the sales agent a 2.0% commission on the aggregate gross proceeds from any stock sales. The Placement Shares will be issued under the registration statement and a prospectus supplement filed on July 17, 2026, and the program will terminate when all such shares are sold or the agreement is ended by either party. A legal opinion from Lucosky Brookman LLP on the validity of the Placement Shares is included as an exhibit.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 1.01, 9.01
2 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Sales agent commission: 2.0% of aggregate gross proceeds
Common stock par value: $0.00001 per share
Form S-3 file number: 333-296550
+3 more
6 metrics
Sales agent commission
2.0% of aggregate gross proceeds
Commission payable on each sale of common stock under the Sales Agreement
Common stock par value
$0.00001 per share
Par value of NanoViricides common stock offered under the program
Form S-3 file number
333-296550
Shelf Registration Statement used for the Placement Shares
Sales Agreement date
July 17, 2026
Date NanoViricides entered the At Market Issuance Sales Agreement
S-3 initial filing date
June 5, 2026
Date the Form S-3 shelf registration was initially filed
S-3 effective date
June 15, 2026
Date the Form S-3 shelf registration was declared effective
Key Terms
At Market Issuance Sales Agreement, at the market offering, Registration Statement on Form S-3, prospectus supplement, +1 more
5 terms
At Market Issuance Sales Agreement financial
"entered into an At Market Issuance Sales Agreement (the “Sales Agreement”)"
An at market issuance sales agreement is a setup where a company arranges for an agent to sell newly issued shares directly into the public market at the current trading price, usually over time as needed. It matters to investors because it gives the company quick, flexible access to cash without setting a fixed price, but can dilute existing shareholders and affect the stock’s supply and short‑term price behavior—like a shop owner adding extra items to a shelf and selling them at whatever the going price is.
at the market offering financial
"in an “at the market” offering as defined in Rule 415(a)(4)"
An at-the-market offering is a way a company raises cash by selling newly issued shares directly into the open market at prevailing prices, rather than all at once in a single deal. Think of it like turning a faucet on to drip shares into trading at current prices when needed; it gives the company flexibility to raise funds over time but can dilute existing shareholders and potentially affect the stock price, which investors should monitor.
Registration Statement on Form S-3 regulatory
"under its existing shelf Registration Statement on Form S-3 (File No. 333-296550)"
A registration statement on Form S‑3 is a short, standardized filing a qualified public company uses to register new securities with regulators so they can be sold to investors; think of it as a pre-approved, reusable permission slip that speeds up future offerings. It matters to investors because it lets the company raise money more quickly and cheaply — which can fund growth or pay debt — but may also lead to share dilution or change in ownership, so it affects value and liquidity.
prospectus supplement regulatory
"filed a prospectus supplement with the U.S. Securities and Exchange Commission"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
Rule 415(a)(4) regulatory
"“at the market” offering as defined in Rule 415(a)(4) under the Securities Act"
Rule 415(a)(4) is a U.S. Securities and Exchange Commission rule that lets a company add more securities to an already effective shelf registration, so those additional shares or bonds can be sold later without filing a completely new registration. For investors it matters because it gives the issuer the flexibility to raise cash quickly—like having an open credit line—while creating the possibility of dilution or changes in supply that can affect share price.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What agreement did NanoViricides (NNVC) enter on July 17, 2026?
NanoViricides entered an At Market Issuance Sales Agreement with D. Boral Capital LLC. This allows it to sell common stock from time to time in an “at the market” offering under its Form S-3 shelf registration.
What commission will D. Boral Capital LLC receive from NNVC’s stock sales?
D. Boral Capital LLC will receive a 2.0% commission on the aggregate gross proceeds from each sale of NanoViricides common stock. This commission applies to all Placement Shares sold through or to the sales agent under the At Market Issuance Sales Agreement.
When does NanoViricides’ at-the-market offering program end?
The at-the-market program ends upon the earlier of selling all Placement Shares covered by the sales agreement or termination of the agreement. Either NanoViricides or D. Boral Capital LLC may terminate the agreement according to its stated terms and conditions.
What legal opinions support NanoViricides’ new at-the-market offering?
NanoViricides filed an opinion from Lucosky Brookman LLP as Exhibit 5.1, addressing the validity of the Placement Shares. A related consent is included in Exhibit 23.1, and the At Market Issuance Sales Agreement itself is filed as Exhibit 1.1.